Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gdynia – page 3

232 clinical trials in Gdynia, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gdynia at a glance
232
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

232 trials in Gdynia

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Dermatitis atopic

Recruiting

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Chronic lymphocytic leukaemia+1

Recruiting

A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gdynia

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory viral infections, particularly evaluating new vaccines for elderly populations. Studies target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

  • Vaccine development for RSV
  • Prevention of respiratory infections
  • Immune response studies
02 Autoimmune Conditions

Comprehensive research into treatments for various autoimmune disorders, including psoriatic arthritis and plaque psoriasis. Studies evaluate novel therapeutics like zasocitinib and tildrakizumab.

  • Psoriasis management
  • Inflammatory bowel disease treatments
  • Arthritis therapies
03 Cardiovascular Research

Innovative trials investigating treatments for heart failure prevention and cardiovascular disease. Studies examine combination therapies and novel compounds for improving cardiac outcomes.

  • Heart failure prevention
  • Cardiovascular risk reduction
  • Combination therapy evaluation
04 Oncology Studies

Advanced research in breast cancer and prostate cancer treatments, focusing on metastatic disease and novel therapeutic combinations.

  • Metastatic breast cancer therapy
  • Prostate cancer treatment
  • Combination therapy approaches
Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.